a provider of drug development services
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
MABBX | 10.08 | N/A | N/A |
Morgan Stanley US Focus Real Estate C | |||
OLVCX | 21.62 | -0.13 | -0.60% |
JPMorgan Large Cap Value C | |||
ZVNBX | 37.39 | -0.76 | -1.99% |
Zevenbergen Growth Investor | |||
NBSMX | 51.80 | -1.08 | -2.04% |
Neuberger Berman Small Cap Growth Instl | |||
BMCAX | 25.81 | -0.55 | -2.09% |
BlackRock Advantage Large Cap Gr Inv A |
A.I.dvisor tells us that CRBP and DYN have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRBP and DYN's prices will move in lockstep.
Ticker / NAME | Correlation To CRBP | 1D Price Change % | ||
---|---|---|---|---|
CRBP | 100% | -5.36% | ||
DYN - CRBP | 28% Poorly correlated | -6.33% | ||
GRI - CRBP | 27% Poorly correlated | -19.57% | ||
SRZN - CRBP | 26% Poorly correlated | -4.91% | ||
DRMA - CRBP | 26% Poorly correlated | -5.79% | ||
NVO - CRBP | 26% Poorly correlated | -3.40% | ||
More |